Exicure, Inc.
$3.77
▲
0.24%
2026-04-21 10:21:00
www.exicuretx.com
NCM: XCUR
Explore Exicure, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$22.85 M
Current Price
$3.77
52W High / Low
$12.65 / $3.1
Stock P/E
—
Book Value
$0.62
Dividend Yield
—
ROCE
-99.65%
ROE
-92.47%
Face Value
—
EPS
$-0.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
4.01
Debt / Equity
4.48
Current Ratio
1.19
Quick Ratio
1.19
Forward P/E
-4.91
Price / Sales
—
Enterprise Value
$20.5 M
EV / EBITDA
-2.08
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 2. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 3. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
| 4. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 5. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 6. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 7. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.26 M | -2.39 M | -2.45 M | -3.02 M | -1.44 M | — |
| Net Profit | -2.9 M | -2.44 M | -2.62 M | 3.01 M | -7.18 M | — |
| EPS in Rs | -0.45 | -0.38 | -0.41 | 0.47 | -1.13 | -0.57 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.5 M | 0 M | 28.83 M |
| Operating Profit | -10.12 M | -4.95 M | -13.14 M | -1.83 M |
| Net Profit | -4.95 M | -9.7 M | -16.91 M | -2.58 M |
| EPS in Rs | -0.78 | -1.52 | -2.65 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.04 M | 15.06 M | 11.58 M | 23.33 M |
| Total Liabilities | 10.12 M | 8.28 M | 8.55 M | 8.41 M |
| Equity | 3.93 M | 6.77 M | 3.03 M | 14.92 M |
| Current Assets | 4.62 M | 13.67 M | 2.02 M | 10.05 M |
| Current Liabilities | 3.89 M | 3.07 M | 2.51 M | 1.64 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.55 M | -2.91 M | -10.36 M | -35.66 M |
| Investing CF | -1.81 M | 0 M | -1.08 M | 4.7 M |
| Financing CF | 1.6 M | 13.4 M | 3.67 M | -3.1 M |
| Free CF | -8.56 M | -2.91 M | -10.36 M | -35.67 M |
| Capex | -0 M | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | -100% | — |
| Earnings Growth % | 49.02% | 42.65% | -555.07% | — |
| Profit Margin % | — | -1940.2% | — | -8.96% |
| Operating Margin % | — | -989.8% | — | -6.35% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -1770.2% | — | 0.27% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-28 | 1:0.2 |
| 2022-06-30 | 1:0.0333333 |